Veterinary Practice Management Software
Two companies hold 79% of a $718M market, and the larger one sells the software to pull revenue from its own diagnostic analysers. It can price the software at zero forever. A software-only entrant cannot answer that.
The buyer population — Veterinary services
Base industry report for 541940 →- Establishments · CanadaA
- 3,417
- Under 10 employeesA
- 56%
- Establishments · USA
- 34,000
- Employment · USA
- 468,624
- Payroll · USA
- $22.7B
Of 3,417 Canadian establishments with employees, 56% have fewer than ten — mostly small operators. Each of those is one potential account, before any filter for size or fit.
Entry signal — what decides who wins here
Structure decidesThe binding constraint is not executional. Being better than the incumbent does not, by itself, get you in — this one is cleared with capital, an asset, or a permission.
Measured, not forecast: the share of US establishments opening in one year that were still active later. It counts good operators and bad ones together, which is exactly why it is the honest answer to “what are the odds”. It is for the whole sector rather than this market, and the ten-year figure comes from an older cohort because no younger one has reached ten years.
This is not a probability of success, and it is not a verdict on you. No survival probability is published per market, and inventing one would be worse than saying so. What the bar reads is how much of the outcome sits inside an operator's control: green means the hurdles are ones a better operator clears, red means the binding constraint is capital, an asset or a permission rather than execution. Someone arriving with an advantage this screen did not assume can win a market shown in red.
Companies named in this market · 8
The proposition being tested
Entering veterinary services with Cloud practice information management for veterinary clinics for Independent and corporate-group veterinary practices.
Sectors joined: Pet Services · Pet Health
[UNVERIFIED] Sector-to-NAICS mapping is analyst judgment — see data/angel-sector-map.json. Counts are a per-record cross-reference and are not additive across records.
Screen score
5.50Analyst judgment calibrated to the cited evidence, not measurement. Method
The incumbent
Who owns this market, how they are defended, and the specific gap their defence leaves open.
None that survives the razor-and-blade economics. This is the cohort's clearest walk
The field
Every vendor named on this record, and what each one discloses. Most disclose nothing, which is why the market is not sized.
Competitor set · 4 named · 0 disclose revenue
| Name | Revenue | Share | Note |
|---|---|---|---|
| IDEXX (veterinary software, services and imaging systems)NASDAQ: IDXXA | not disclosed | — | Group revenue $4,304M in 2025, up 10%; the software, services and imaging line grew 13% but is not broken out. ezyVet and Neo passed 10,000 locations — an installed-base count, which is the closest thing to a share figure anyone publishes here |
| Covetrus (Pulse)C | not disclosed | — | Private since its 2022 take-private; Pulse and the distribution business report no software line |
| Patterson Companies (Cornerstone, NaVetor)C | not disclosed | — | Animal-health distributor; software inside the segment with no line reported |
| Vetspire / Shepherd / DigitailC | not disclosed | — | Private, venture-funded challengers competing on interface and specialisation |
Nobody here publishes revenue. The market is not sized for that reason — an estimate built on nothing would only look like knowledge.
Startups & challengers
Newer and smaller vendors going at the incumbent — funded challengers first. Named, not researched to the depth of the field above; a company with a page here links to it.
| Company | Stage | What it does | Raised |
|---|---|---|---|
| Nectar Vet | Startup | Cloud practice management and payments for veterinary clinics | — |
| Sherpherd | Startup | Cloud practice management software for veterinary clinics | — |
Demand landscape
Addressable market, competitor positions, and where buyer preference is shifting.
A second source quotes 12.7% CAGR on a different base. Either way this is the smallest addressable market in the vertical cohort by a wide margin.
Roughly the 21% of the market not held by IDEXX or Covetrus, already split between three named challengers.
Contesting the 21% tail against DaySmart, Hippo and Practice Vantage — who are already there.
Demand indicators
Competitor positions
Also sells the in-clinic diagnostic analysers and consumables the software orders from. The software is a distribution channel.
Animal health distributor. Same structure — software attached to product supply.
Largest independent.
Cloud challenger.
Cloud challenger.
Unusually complete share data for a category this size — the five figures sum to 100%, which is itself a sign of how few participants there are.
Shifting buyer preferences
- Cloud adoption is the live migration, and both duopolists already have cloud products.
- Corporate groups buy centrally, which concentrates the decision into very few hands.
- Public and regulatory scrutiny of PE-driven price increases is rising — a reputational overhang on the whole sector.
- Clinics increasingly resent the analyser-software bundle, but resentment without an alternative supply of diagnostics is not leverage.
Revenue model
Pricing that a real buyer would clear, the volume that follows, and what else the same customer will pay for.
Pricing
The published range for independent PIMS — and the incumbent can undercut all of it from diagnostics margin.
Structurally capped, and by a mechanism the entrant cannot replicate: a competitor that makes its money on consumables can give the software away and still profit.
Volume projection
No projection is offered. Producing one would lend false precision to a market this study recommends walking away from.
Ancillary revenue
The adjacent revenue in this market IS diagnostics, and it belongs to the incumbent.
Cost structure
What it costs to stand this up and keep it running — and where the supply chain can end the business.
Fixed costs, annual
Unpriced and possibly unavailable. Integrating with IDEXX analysers requires IDEXX's cooperation, and IDEXX owns 43% of the software market.
Variable costs
Standard, and not the problem.
Long cycles into centralised buyers who already have enterprise agreements with the duopoly.
Supply chain
The worst position in the portfolio. The dominant competitor also manufactures the diagnostic hardware every clinic runs, and practice software must integrate with it to be usable. You would be asking your largest competitor for the integration that makes your product viable — and they can refuse, or grant it and undercut you on price at zero marginal cost.
Labour — Canadian and US medians
| Role | CA median | US median |
|---|---|---|
| Veterinarians | $124,800 | — |
| Veterinary Technologists and Technicians | $47,840 | — |
| Software Developers | $100,006 | $135,980 |
Nothing about the labour economics saves this. The constraint is competitive structure, not cost.
Execution & risk factors
Regulatory hurdles, whether anything defends the position once it works, and the macro trends acting on it.
Macro trends
Real, and entirely captured by the duopoly.
Concentrates the buyer into a handful of corporate groups with existing enterprise agreements — fewer doors, all guarded.
The decisive factor. Software subsidised by consumables cannot be beaten on price by software alone.
Could unsettle the incumbents, but reaches the clinic owner rather than the software vendor.
Kill criteria
The findings that should end this today. Written on the assumption that the reader is too invested to see them unaided.
IDEXX can price practice software at zero and still profit, because the software exists to order its analysers and consumables. No software-only entrant has an answer to this.
79% of a $718M market sits with two companies. The contestable remainder is roughly $150M, already divided among three named challengers.
Analyser integration requires the cooperation of the company holding 43% share. Building a veterinary PIMS that cannot talk to the clinic's analysers is building a product nobody can use.
Where the industry talks
The associations, forums and events where people in this trade actually talk shop — where to listen before entering, and where the first customers are found. Each link was opened on the date shown.
National body for Canada's veterinarians; continuing education, practice resources and workforce advocacy.
Provincial association; continuing education, member benefits and a practice classifieds board.
For practice managers rather than veterinarians; certification and management courses.
Subscription message boards; the site describes itself as the largest online community for veterinarians.
Practice accreditation body; blocked automated access (Cloudflare challenge).
vmx.org did not resolve and the NAVC site blocks automated access, so the VMX conference is not listed; dvm360.com is behind Cloudflare.
Full study
The complete written report.
Market-Entry Study — Veterinary Practice Management Software
NAICS 541940 · Veterinary services
Verdict: WALK — razor-and-blade economics the entrant cannot replicate.
Prepared 2026-09-08 · Evidence tiers per ../_method/screening-model.md
The proposition being tested
Entering veterinary practice information management with a cloud PIMS for independent and corporate-group veterinary practices.
1. MARKET SIZE
| Metric | Value | Tier |
|---|---|---|
| Veterinary PMS market, 2026 | $718.1M | [B] |
| Projected 2032 | $1,230M, 9.3% CAGR (a second source quotes 12.7%) | [B] |
| IDEXX share (ezyVet + Neo) | 43% | [B] |
| Covetrus share (Pulse) | 36% | [B] |
| Combined duopoly | 79% | [B] |
| DaySmart Vet / Hippo / Practice Vantage | 11% / 5% / 5% | [B] |
| PE and corporate ownership of US clinics | 30–50%, up from <10% a decade ago | [B] |
| PE capital into the veterinary sector | $51.6B, plus $9.3B in the first four months of 2024 | [B] |
| Reported price increases for routine services | Up to 100% in some cases | [B] |
The share figures sum to 100% — unusually complete data, and itself a sign of how few participants exist. This is the smallest addressable market in the vertical cohort by a wide margin, and 79% of it is held by two companies.
Growing or shrinking: growing on a small base, entirely captured. Growth is not the problem here.
Demand signals
- Share data: STRONG, tier [B], and complete. Rare for a category this size.
- Consolidation data: STRONG, tier [B]. $51.6B of PE capital, 30–50% clinic ownership.
- Public scrutiny: RISING [B]. Price increases of up to 100% are drawing regulatory and press attention — a reputational overhang on the sector, not an opening for a software entrant.
- Search volume: NOT MEASURED, and not worth measuring given section 3.
2. THE CUSTOMER
What they want
A cloud PIMS that is modern, reliable, and not tied to a diagnostics supplier. Clinics genuinely resent the analyser-software bundle.
But resentment without an alternative supply of diagnostics is not leverage. The clinic must run diagnostics; the diagnostics come from IDEXX or a small number of peers; the software orders them. The customer's dissatisfaction is real and commercially inert.
What they pay for right now
| Current spend | Typical cost |
|---|---|
| PIMS licence | $3,600–$12,000 per practice per year [UNVERIFIED range] |
| Diagnostic analysers and consumables | The dominant spend — and the reason the software is priced the way it is |
| Corporate group enterprise agreements | Negotiated centrally, covering both |
3. THE COMPETITION
| Player | Share | Note |
|---|---|---|
| IDEXX (ezyVet + Neo) | 43% | Also manufactures the in-clinic diagnostic analysers and consumables the software orders from. |
| Covetrus (Pulse) | 36% | Animal health distributor. Same structure — software attached to product supply. |
| DaySmart Vet | 11% | Largest independent |
| Hippo | 5% | Cloud challenger |
| Practice Vantage | 5% | Cloud challenger |
The structural fact that ends this study
IDEXX does not sell practice software to make money on practice software. It sells it to route diagnostic orders to its own analysers and consumables. The software is a distribution channel for a hardware-and-reagents business.
Three consequences, all fatal to a software-only entrant:
- IDEXX can price the software at zero and still profit. No software company can match a competitor whose product is a loss leader for something else.
- Analyser integration requires IDEXX's cooperation. A PIMS that cannot talk to the clinic's analysers is unusable — so you would be asking the holder of 43% share for the integration that makes your product viable.
- The contestable remainder is ~21% of $718M — roughly $150M — already split among three named challengers.
This is the same trap identified in the HRM study, where incumbents subsidise software from benefits commissions and payroll float. Whoever owns the adjacent revenue stream sets the software price. Here, the adjacent revenue is the business.
Where they are weak
IDEXX and Covetrus both carry the usual incumbent complaints — dated workflows, bundling resentment, uneven support. None of it is actionable for the reason above.
4. ENTRY STRATEGY
#1 — Contest the 21% independent tail. Cost: $400k+. Odds: low. Against DaySmart, Hippo and Practice Vantage, who are already there, for a share of roughly $150M — while the two majors can undercut on price at will.
#2 — Sell into corporate groups. Cost: $600k+. Odds: very low. Long cycles into centralised buyers who already hold enterprise agreements covering software and diagnostics together.
#3 — Build a full PIMS with analyser integration. Cost: unpriced and possibly unavailable. Requires the cooperation of a competitor holding 43% share.
None of these is recommended.
What would have to be true
- IDEXX chooses not to price aggressively against a new entrant. It has every incentive to, and the margin to fund it indefinitely.
- Analyser integration is obtainable on commercial terms. Unverified, and controlled by the competitor.
- The ~$150M contestable tail supports a fourth challenger. Three are already there.
No 30-day test is proposed. The kill condition is structural and already established; no customer conversation changes the arithmetic.
5. KILL CRITERIA
1. IDEXX can price practice software at zero and still profit, because the software exists to order its analysers and consumables. A software-only entrant has no answer to a competitor for whom the product is a channel, not a business.
2. 79% of a $718M market sits with two companies, and the contestable remainder — roughly $150M — is already divided among three named challengers. The smallest market in the cohort with the highest concentration.
3. Analyser integration requires the cooperation of the company holding 43% share. Building a veterinary PIMS that cannot talk to the clinic's analysers is building a product nobody can use.
The honest bias check: the veterinary sector is genuinely sympathetic territory — $51.6B of private equity, clinic prices up as much as 100%, public scrutiny building. It is easy to translate "this industry has problems" into "there is an opportunity here." There is. It just is not in practice software. Sympathy for the customer is not a market thesis, and the razor-and-blade structure is indifferent to how deserving the independent clinic is.
THE CALL: WALK
Walk. No trigger reopens this, because the kill condition is a business model rather than a market condition.
The evidence: a $718.1M market [B] — smallest in the cohort — with 79% held by two companies [B], the larger of which monetises diagnostics rather than software and can therefore price software at zero indefinitely, and whose cooperation is required for the analyser integration that makes any competing product usable.
The one adjacent thing worth doing
The opening in this sector is not practice software — it is the consequence of consolidation. With $51.6B of PE invested, 30–50% of clinics corporately owned, and reported price increases up to 100% drawing regulatory scrutiny, there is room for tooling that serves independent clinics competing against corporate groups, or that serves the groups' own portfolio operations. Both sit outside the razor-and-blade trap. That is a different study.
STRUCTURED ANALYSIS
Four dimensions — demand landscape, revenue model, cost structure, and
execution & risk factors — are held as structured data in
profile.json rather than repeated as prose here, so there is
exactly one source of truth for every figure. The Market Research app renders
all four as panels above this report.
Sources
- Business Research Insights — Veterinary Practice Management Software Market, CAGR 12.7%
- The Business Research Company — Veterinary Practice Management Software Market 2026, Share
- PMC — Cloud-Based Software is Gathering Steam (veterinary PIMS share data)
- AAHA — Corporate consolidation and the rise of private equity
- PBS NewsHour — As veterinary costs climb, private equity ownership of clinics draws scrutiny
- American Economic Liberties Project — Private Equity's Stealthy Vet Takeover
- CT Acquisitions — Private Equity Veterinary (2026): The Consolidation Report
- Wage data:
../../occupation/data/build/site-data.json